Terms: = Endocrine gland cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Treatment
197 results:
1. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
[TBL] [Abstract] [Full Text] [Related]
2. HSF-1/miR-145-5p transcriptional axis enhances hyperthermic intraperitoneal chemotherapy efficacy on peritoneal ovarian carcinosis.
Di Agostino S; Canu V; Donzelli S; Pulito C; Sacconi A; Ganci F; Valenti F; Goeman F; Scalera S; Rollo F; Bagnato A; Diodoro MG; Vizza E; Carosi M; Rufini B; Federici O; Giofrè M; Carboni F; Muti P; Ciliberto G; Strano S; Valle M; Blandino G
Cell Death Dis; 2023 Aug; 14(8):535. PubMed ID: 37598177
[TBL] [Abstract] [Full Text] [Related]
3. Intraoperative pancreatoscopy can improve the detection of skip lesions during surgery for intraductal papillary mucinous neoplasia: A pilot study.
Arnelo U; Valente R; Scandavini CM; Halimi A; Mucelli RMP; Rangelova E; Svensson J; Schulick RD; Torphy RJ; Fagerström N; Moro CF; Vujasinovic M; Matthias Löhr J; Del Chiaro M
Pancreatology; 2023 Sep; 23(6):704-711. PubMed ID: 37336668
[TBL] [Abstract] [Full Text] [Related]
4. Visualization research on ENT1/NIS dual-function gene therapy to reverse drug resistance mediated by muc1 in GEM-resistant pancreatic cancer.
Xi Y; Chen H; Xi Y; Hai W; Qu Q; Zhang M; Li B
Nucl Med Biol; 2023; 120-121():108350. PubMed ID: 37229950
[TBL] [Abstract] [Full Text] [Related]
5. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic cancer Cells Through Inhibition of muc1 Expression.
Wei D; Wang L; Liu Y; Hafley MA; Tan L; Lorenzi PL; Yang P; Zuo X; Bresalier RS
Dig Dis Sci; 2023 Jul; 68(7):3043-3058. PubMed ID: 37071246
[TBL] [Abstract] [Full Text] [Related]
6. Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines.
Tamburello M; Abate A; Rossini E; Basnet RM; Zizioli D; Cosentini D; Hantel C; Laganà M; Tiberio GAM; Grisanti S; Memo M; Berruti A; Sigala S
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047801
[TBL] [Abstract] [Full Text] [Related]
7. Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian cancer: A Multicenter GINECO RETROLA Cohort Study.
Bourien H; Lefevre LB; Mouret-Reynier MA; Asselain B; Lucas B; Gavoille C; Cornila C; Gavoille L; Colomba E; Patsouris A; Fabbro M; Chakiba C; Toussaint P; Simon H; Berton D; Garbay D; Tixidre CG; Coeffic D; Morvan A; Collard O; DE LA Motte Rouge T
Anticancer Res; 2023 Feb; 43(2):653-662. PubMed ID: 36697069
[TBL] [Abstract] [Full Text] [Related]
8. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models.
Abate A; Tamburello M; Rossini E; Basnet RM; Ribaudo G; Gianoncelli A; Hantel C; Cosentini D; Laganà M; Grisanti S; Tiberio GAM; Memo M; Berruti A; Sigala S
Endocr Relat Cancer; 2023 Feb; 30(2):. PubMed ID: 36449565
[TBL] [Abstract] [Full Text] [Related]
9. Primary leiomyosarcoma of ovary: A rare malignancy as an incidental finding.
Raychaudhuri S; Sidam D; Jain M; Chawla R; Pujani M; Wadhwa R
Indian J Pathol Microbiol; 2022; 65(4):938-941. PubMed ID: 36308213
[TBL] [Abstract] [Full Text] [Related]
10. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract] [Full Text] [Related]
11. Altered muc1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer.
Hong J; Guo G; Wu S; Lin S; Zhou Z; Chen S; Ye C; Li J; Lin W; Ye Y
J Leukoc Biol; 2022 Dec; 112(6):1577-1590. PubMed ID: 36222123
[TBL] [Abstract] [Full Text] [Related]
12. Targeting tumor-associated muc1 overcomes anoikis-resistance in pancreatic cancer.
Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
[TBL] [Abstract] [Full Text] [Related]
13. Comparative study on the antitumor effects of gemcitabine polybutylcyanoacrylate nanoparticles coupled with anti-human muc1 and CA199 monoclonal antibodies on pancreatic cancer in vitro and in vivo.
Zhang L; Hou Y; Li C; Liu H; Wang Y
Arab J Gastroenterol; 2022 Nov; 23(4):263-269. PubMed ID: 35922259
[TBL] [Abstract] [Full Text] [Related]
14. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract] [Full Text] [Related]
15. Orthotopic and Heterotopic Murine Models of Pancreatic cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
Front Immunol; 2022; 13():863346. PubMed ID: 35874730
[TBL] [Abstract] [Full Text] [Related]
16. Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
Warde KM; Lim YJ; Ribes Martinez E; Beuschlein F; O'Shea P; Hantel C; Dennedy MC
Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35797592
[TBL] [Abstract] [Full Text] [Related]
17. Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Kahn RM; Ragupathi G; Zhou QC; Iasonos A; Kravetz S; Hensley ML; Konner JA; Makker V; Tew WP; Aghajanian C; Sabbatini PJ; O'Cearbhaill RE
Cancer Immunol Immunother; 2023 Jan; 72(1):183-191. PubMed ID: 35779095
[TBL] [Abstract] [Full Text] [Related]
18. A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
Zhang L; Zhu J; Hou Y; Li C; Liu H
J Cancer Res Ther; 2021 Dec; 17(7):1702-1708. PubMed ID: 35381742
[TBL] [Abstract] [Full Text] [Related]
19. [Pituicytoma: a clinicopathological analysis of twenty-one cases].
Feng X; Bao W; Wang X; Rao Q; Shi QL; Yue Z
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):314-318. PubMed ID: 35359042
[No Abstract] [Full Text] [Related]
20. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract] [Full Text] [Related]
[Next]
